Cargando…
Population Pharmacokinetics and Pharmacodynamics Modeling of Torasemide and Furosemide After Oral Repeated Administration in Healthy Dogs
Torasemide is a loop diuretic licensed in dogs for cardiogenic pulmonary oedema. The aim of this pharmacokinetic-pharmacodynamic (PK/PD) study was to define an optimally effective dosage regimen based on preclinical data. In a first study, 5 dogs received once-daily oral torasemide (0, 0.1, 0.2, 0.4...
Autores principales: | Pelligand, Ludovic, Guillot, Emilie, Geneteau, Anne, Guyonnet, Jerome, Magnier, Reynald, Elliott, Jonathan, Peyrou, Mathieu, Jacobs, Matthieu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199743/ https://www.ncbi.nlm.nih.gov/pubmed/32411731 http://dx.doi.org/10.3389/fvets.2020.00151 |
Ejemplares similares
-
Safety of torasemide in healthy adult dogs administered daily for 26 weeks
por: Coussanes, Evelyne, et al.
Publicado: (2021) -
Pharmacokinetic and pharmacodynamic properties of orally administered torasemide in healthy cats
por: Roche‐Catholy, Marine, et al.
Publicado: (2022) -
Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure
por: Ballester, Maria Rosa, et al.
Publicado: (2015) -
Impact of Albumin Binding Function on Pharmacokinetics and Pharmacodynamics of Furosemide
por: Klinkmann, Gerd, et al.
Publicado: (2022) -
Short‐Term Efficacy and Safety of Torasemide and Furosemide in 366 Dogs with Degenerative Mitral Valve Disease: The TEST Study
por: Chetboul, V., et al.
Publicado: (2017)